16.68
price up icon1.03%   0.17
after-market Dopo l'orario di chiusura: 16.69 0.01 +0.06%
loading
Precedente Chiudi:
$16.51
Aprire:
$16.43
Volume 24 ore:
297.23K
Relative Volume:
0.88
Capitalizzazione di mercato:
$428.51M
Reddito:
-
Utile/perdita netta:
$11.77M
Rapporto P/E:
28.83
EPS:
0.5785
Flusso di cassa netto:
$-19.23M
1 W Prestazione:
+8.88%
1M Prestazione:
+2.61%
6M Prestazione:
-35.94%
1 anno Prestazione:
+23.37%
Intervallo 1D:
Value
$15.93
$17.04
Intervallo di 1 settimana:
Value
$15.15
$17.04
Portata 52W:
Value
$11.56
$29.79

Tourmaline Bio Inc Stock (TRML) Company Profile

Name
Nome
Tourmaline Bio Inc
Name
Telefono
646-481-9832
Name
Indirizzo
27 WEST 24TH STREET, NEW YORK
Name
Dipendente
74
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
TRML's Discussions on Twitter

Confronta TRML con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TRML
Tourmaline Bio Inc
16.68 393.55M 0 11.77M -19.23M 0.5785
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-23 Iniziato Chardan Capital Markets Buy
2025-03-06 Iniziato Wedbush Outperform
2024-12-06 Iniziato BMO Capital Markets Outperform
2024-11-11 Reiterato H.C. Wainwright Buy
2023-12-15 Iniziato Jefferies Buy
2023-12-04 Ripresa H.C. Wainwright Buy
2023-11-17 Iniziato Truist Buy
2023-10-31 Iniziato Guggenheim Buy
2023-10-25 Iniziato Piper Sandler Overweight
2022-10-20 Iniziato H.C. Wainwright Buy
2022-07-05 Downgrade Morgan Stanley Overweight → Equal-Weight
Mostra tutto

Tourmaline Bio Inc Borsa (TRML) Ultime notizie

pulisher
04:15 AM

Deutsche Bank AG Grows Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

04:15 AM
pulisher
May 30, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 30, 2025
pulisher
May 29, 2025

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) - MSN

May 29, 2025
pulisher
May 28, 2025

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results - Insider Monkey

May 28, 2025
pulisher
May 27, 2025

H.C. Wainwright maintains $50 target on Tourmaline Bio stock By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 27, 2025
pulisher
May 26, 2025

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings - Defense World

May 26, 2025
pulisher
May 25, 2025

Tourmaline Bio Shares Drop After Phase 2 Results for Obesity Drug Pacibekitug Fail to Meet Analyst Expectations - geneonline.com

May 25, 2025
pulisher
May 23, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Lifted by Northern Trust Corp - Defense World

May 23, 2025
pulisher
May 21, 2025

BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 21, 2025

BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio stock holds $63 target post-Ph2 data - Investing.com

May 21, 2025
pulisher
May 21, 2025

Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter

May 21, 2025
pulisher
May 21, 2025

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga

May 20, 2025
pulisher
May 20, 2025

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive

May 20, 2025
pulisher
May 20, 2025

Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio (TRML) Reports Encouraging Results from Phase 2 C - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough Clinical Trial: New Quarterly Drug Cuts Heart Disease Risk Marker by 85% in Kidney Disease Patients - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com India

May 20, 2025
pulisher
May 19, 2025

Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan

May 19, 2025
pulisher
May 16, 2025

Tower Research Capital LLC TRC Increases Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 16, 2025
pulisher
May 14, 2025

Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World

May 14, 2025
pulisher
May 12, 2025

Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating - TipRanks

May 12, 2025
pulisher
May 10, 2025

Raymond James Financial Inc. Takes Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World

May 10, 2025
pulisher
May 10, 2025

Barclays PLC Increases Position in Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:REFI) - Defense World

May 10, 2025
pulisher
May 10, 2025

Barclays PLC Acquires 5,175 Shares of Tile Shop Holdings, Inc. (NASDAQ:TTSH) - Defense World

May 10, 2025
pulisher
May 10, 2025

Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World

May 10, 2025
pulisher
May 10, 2025

Barclays PLC Acquires 42,792 Shares of MicroVision, Inc. (NASDAQ:MVIS) - Defense World

May 10, 2025
pulisher
May 10, 2025

Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

FY2025 EPS Estimates for Tourmaline Bio Decreased by Analyst - Defense World

May 09, 2025
pulisher
May 09, 2025

Chardan Capital Raises Earnings Estimates for Tourmaline Bio - Defense World

May 09, 2025
pulisher
May 08, 2025

FY2025 EPS Estimates for Tourmaline Bio Raised by Analyst - Defense World

May 08, 2025
pulisher
May 08, 2025

Tourmaline Bio Q2 EPS Estimate Decreased by HC Wainwright - Defense World

May 08, 2025
pulisher
May 08, 2025

Analysts Set Expectations for Tourmaline Bio Q2 Earnings - Defense World

May 08, 2025
pulisher
May 07, 2025

HC Wainwright Predicts Tourmaline Bio Q2 Earnings - Defense World

May 07, 2025

Tourmaline Bio Inc Azioni (TRML) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):